Literature DB >> 18096867

Haemophilus influenzae lysate induces aspects of the chronic obstructive pulmonary disease phenotype.

Seyed Javad Moghaddam1, Cecilia G Clement, M Miguelina De la Garza, Xiaoyan Zou, Elizabeth L Travis, Hays W J Young, Christopher M Evans, Michael J Tuvim, Burton F Dickey.   

Abstract

Nontypeable Haemophilus influenzae (NTHi) commonly colonizes the lower airways of patients with chronic obstructive pulmonary disease (COPD). Whether it contributes to COPD progression is unknown. Here, we determined which aspects of the COPD phenotype can be induced by repetitive exposure to NTHi products. Mice were exposed weekly to an aerosolized NTHi lysate, and inflammation was evaluated by measurement of cells and cytokines in bronchoalveolar lavage fluid (BALF) and immunohistochemical staining; structural changes were evaluated histochemically by periodic acid fluorescent Schiff's reagent, Masson's trichrome, and Picrosirius red staining; mucin gene expression was measured by quantitative RT-PCR; and the role of TNF-alpha was examined by transgenic airway overexpression and use of an inhibitory antibody. NTHi lysate induced rapid activation of NF-kappaB in airway cells and increases of inflammatory cytokines and neutrophils in BALF. Repetitive exposure induced infiltration of macrophages, CD8+ T cells, and B cells around airways and blood vessels, and collagen deposition in airway and alveolar walls, but airway mucin staining and gel-forming mucin transcripts were not increased. Transgenic overexpression of TNF-alpha caused BALF neutrophilia and inflammatory cell infiltration around airways, but not fibrosis, and TNF-alpha neutralization did not reduce BALF neutrophilia in response to NTHi lysate. In conclusion, NTHi products elicit airway inflammation in mice with a cellular and cytokine profile similar to that in COPD, and cause airway wall fibrosis but not mucous metaplasia. TNF-alpha is neither required for inflammatory cell recruitment nor sufficient for airway fibrosis. Colonization by NTHi may contribute to the pathogenesis of small airways disease in patients with COPD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18096867      PMCID: PMC2396243          DOI: 10.1165/rcmb.2007-0366OC

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  74 in total

1.  Comparison of the structural and inflammatory features of COPD and asthma. Giles F. Filley Lecture.

Authors:  P K Jeffery
Journal:  Chest       Date:  2000-05       Impact factor: 9.410

Review 2.  Chronic obstructive pulmonary disease.

Authors:  P J Barnes
Journal:  N Engl J Med       Date:  2000-07-27       Impact factor: 91.245

3.  Airway inflammation and bronchial microbial patterns in patients with stable chronic obstructive pulmonary disease.

Authors:  N Soler; S Ewig; A Torres; X Filella; J Gonzalez; A Zaubet
Journal:  Eur Respir J       Date:  1999-11       Impact factor: 16.671

Review 4.  Haemophilus influenzae in chronic bronchitis.

Authors:  T F Murphy
Journal:  Semin Respir Infect       Date:  2000-03

Review 5.  Evidence of bacterial infection in acute exacerbations of chronic bronchitis.

Authors:  R Wilson
Journal:  Semin Respir Infect       Date:  2000-09

6.  Characterization of adherence of nontypeable Haemophilus influenzae to human epithelial cells.

Authors:  M van Schilfgaarde; P van Ulsen; P Eijk; M Brand; M Stam; J Kouame; L van Alphen; J Dankert
Journal:  Infect Immun       Date:  2000-08       Impact factor: 3.441

Review 7.  Role of neutrophil elastase in hypersecretion during COPD exacerbations, and proposed therapies.

Authors:  J A Nadel
Journal:  Chest       Date:  2000-05       Impact factor: 9.410

8.  Immunohistochemical localization of mouse Clara cell 10-KD protein using antibodies raised against the recombinant protein.

Authors:  M K Ray; G Wang; J Barrish; M J Finegold; F J DeMayo
Journal:  J Histochem Cytochem       Date:  1996-08       Impact factor: 2.479

9.  Bacterial infection in chronic obstructive pulmonary disease. A study of stable and exacerbated outpatients using the protected specimen brush.

Authors:  E Monsó; J Ruiz; A Rosell; J Manterola; J Fiz; J Morera; V Ausina
Journal:  Am J Respir Crit Care Med       Date:  1995-10       Impact factor: 21.405

10.  Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma.

Authors:  V M Keatings; P D Collins; D M Scott; P J Barnes
Journal:  Am J Respir Crit Care Med       Date:  1996-02       Impact factor: 21.405

View more
  61 in total

1.  Cross-talk between PKA-Cβ and p65 mediates synergistic induction of PDE4B by roflumilast and NTHi.

Authors:  Seiko Susuki-Miyata; Masanori Miyata; Byung-Cheol Lee; Haidong Xu; Hirofumi Kai; Chen Yan; Jian-Dong Li
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-23       Impact factor: 11.205

2.  Interleukin 6, but not T helper 2 cytokines, promotes lung carcinogenesis.

Authors:  Cesar E Ochoa; Seyedeh Golsar Mirabolfathinejad; Venado Ana Ruiz; Scott E Evans; Mihai Gagea; Christopher M Evans; Burton F Dickey; Seyed Javad Moghaddam
Journal:  Cancer Prev Res (Phila)       Date:  2010-11-22

Review 3.  Inhaled innate immune ligands to prevent pneumonia.

Authors:  Scott E Evans; Michael J Tuvim; Cory J Fox; Nidhi Sachdev; Leonid Gibiansky; Burton F Dickey
Journal:  Br J Pharmacol       Date:  2011-05       Impact factor: 8.739

4.  Synergistic interactions of TLR2/6 and TLR9 induce a high level of resistance to lung infection in mice.

Authors:  Jeffrey M Duggan; Dahui You; Jeffrey O Cleaver; Derek T Larson; R Joshua Garza; Francisco A Guzmán Pruneda; Michael J Tuvim; Jiexin Zhang; Burton F Dickey; Scott E Evans
Journal:  J Immunol       Date:  2011-04-11       Impact factor: 5.422

Review 5.  Mucus hypersecretion in asthma: causes and effects.

Authors:  Christopher M Evans; Kyubo Kim; Michael J Tuvim; Burton F Dickey
Journal:  Curr Opin Pulm Med       Date:  2009-01       Impact factor: 3.155

6.  Airway and lung pathology due to mucosal surface dehydration in {beta}-epithelial Na+ channel-overexpressing mice: role of TNF-{alpha} and IL-4R{alpha} signaling, influence of neonatal development, and limited efficacy of glucocorticoid treatment.

Authors:  Alessandra Livraghi; Barbara R Grubb; Elizabeth J Hudson; Kristen J Wilkinson; John K Sheehan; Marcus A Mall; Wanda K O'Neal; Richard C Boucher; Scott H Randell
Journal:  J Immunol       Date:  2009-04-01       Impact factor: 5.422

7.  MyD88 controls airway epithelial Muc5ac expression during TLR activation conditions from agricultural organic dust exposure.

Authors:  John D Dickinson; Jenea M Sweeter; Elizabeth B Staab; Amy J Nelson; Kristina L Bailey; Kristi J Warren; Ana Maria Jaramillo; Burton F Dickey; Jill A Poole
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-10-25       Impact factor: 5.464

8.  Stimulation of lung innate immunity protects against lethal pneumococcal pneumonia in mice.

Authors:  Cecilia G Clement; Scott E Evans; Christopher M Evans; David Hawke; Ryuji Kobayashi; Paul R Reynolds; Seyed J Moghaddam; Brenton L Scott; Ernestina Melicoff; Roberto Adachi; Burton F Dickey; Michael J Tuvim
Journal:  Am J Respir Crit Care Med       Date:  2008-04-03       Impact factor: 21.405

9.  IL6 Blockade Reprograms the Lung Tumor Microenvironment to Limit the Development and Progression of K-ras-Mutant Lung Cancer.

Authors:  Mauricio S Caetano; Huiyuan Zhang; Amber M Cumpian; Lei Gong; Nese Unver; Edwin J Ostrin; Soudabeh Daliri; Seon Hee Chang; Cesar E Ochoa; Samir Hanash; Carmen Behrens; Ignacio I Wistuba; Cinthya Sternberg; Humam Kadara; Carlos Gil Ferreira; Stephanie S Watowich; Seyed Javad Moghaddam
Journal:  Cancer Res       Date:  2016-04-01       Impact factor: 12.701

10.  Allergic lung inflammation alters neither susceptibility to Streptococcus pneumoniae infection nor inducibility of innate resistance in mice.

Authors:  Cecilia G Clement; Michael J Tuvim; Christopher M Evans; Daniel M Tuvin; Burton F Dickey; Scott E Evans
Journal:  Respir Res       Date:  2009-07-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.